The Economics of Personalized Therapy in Metastatic Colorectal Cancer

被引：2

作者：

Jain, Shweta ^{[3
]}

Shankaran, Veena ^{[1
,2
,3
]}

机构：

[1] Univ Washington, Sch Med, Fred Hutchinson Canc Res Ctr, Div Clin Res, 825 Eastlake Ave E,MS G4-830, Seattle, WA 98109 USA

[2] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA

[3] Univ Washington, Sch Med, Div Med Oncol, Seattle, WA 98109 USA

来源：

CURRENT COLORECTAL CANCER REPORTS | 2016年 / 12卷 / 03期

关键词：

Colorectal cancer; Cost-effectiveness; Health economics; Biomarkers; Precision medicine;

D O I：

10.1007/s11888-016-0318-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Though the prognosis for patients with advanced colorectal cancer has improved significantly over the past two decades due to the development of new chemotherapeutics and biologic agents, this progress has come at an increased cost to patients and to the healthcare system. The cost of cancer care in the USA is rising at an alarming rate and far in excess of spending in other developed countries. The identification of predictive biomarkers that can help clinicians target existing and future therapies to patients who are most likely to benefit (and away from patients who would not benefit) has the potential to improve the value of cancer therapy and direct healthcare resources more efficiently. Here, we review established and emerging predictive biomarkers in colorectal cancer treatment and the cost implications of utilizing these markers in clinical practice.

引用

页码：123 / 129

页数：7

共 58 条

[1] American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy [J].

Allegra, Carmen J. ;

Jessup, J. Milburn ;

Somerfield, Mark R. ;

Hamilton, Stanley R. ;

Hammond, Elizabeth H. ;

Hayes, Daniel F. ;

McAllister, Pamela K. ;

Morton, Roscoe F. ;

Schilsky, Richard L. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) :2091-2096

[2] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[3]

Bach P, 2012, NY TIMES, V14, P2012

[4] Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial [J].

Bennouna, Jaafar ;

Sastre, Javier ;

Arnold, Dirk ;

Osterlund, Pia ;

Greil, Richard ;

Van Cutsem, Eric ;

von Moos, Roger ;

Maria Vieitez, Jose ;

Bouche, Olivier ;

Borg, Christophe ;

Steffens, Claus-Christoph ;

Alonso-Orduna, Vicente ;

Schlichting, Christoph ;

Reyes-Rivera, Irmarie ;

Bendahmane, Belguendouz ;

Andre, Thierry ;

Kubicka, Stefan .

LANCET ONCOLOGY, 2013, 14 (01) :29-37

[5] Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing [J].

Caudle, K. E. ;

Thorn, C. F. ;

Klein, T. E. ;

Swen, J. J. ;

McLeod, H. L. ;

Diasio, R. B. ;

Schwab, M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (06) :640-645

[6] Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold [J].

Claxton, Karl ;

Martin, Steve ;

Soares, Marta ;

Rice, Nigel ;

Spackman, Eldon ;

Hinde, Sebastian ;

Devlin, Nancy ;

Smith, Peter C. ;

Sculpher, Mark .

HEALTH TECHNOLOGY ASSESSMENT, 2015, 19 (14) :1-+

[7] Rates and Patterns of Recurrence Following Curative Intent Surgery for Colorectal Liver Metastasis An International Multi-Institutional Analysis of 1669 Patients [J].

de Jong, Mechteld C. ;

Pulitano, Carlo ;

Ribero, Dario ;

Strub, Jennifer ;

Mentha, Gilles ;

Schulick, Richard D. ;

Choti, Michael A. ;

Aldrighetti, Luca ;

Capussotti, Lorenzo ;

Pawlik, Timothy M. .

ANNALS OF SURGERY, 2009, 250 (03) :440-448

[8] KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab [J].

De Roock, W. ;

Piessevaux, H. ;

De Schutter, J. ;

Janssens, M. ;

De Hertogh, G. ;

Personeni, N. ;

Biesmans, B. ;

Van Laethem, J. -L. ;

Peeters, M. ;

Humblet, Y. ;

Van Cutsem, E. ;

Tejpar, S. .

ANNALS OF ONCOLOGY, 2008, 19 (03) :508-515

[9]

Division of Cancer Treatment and Diagnosis, 2016, NCI SPONS TRIALS PRE

[10] Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer [J].

Douillard, Jean-Yves ;

Oliner, Kelly S. ;

Siena, Salvatore ;

Tabernero, Josep ;

Burkes, Ronald ;

Barugel, Mario ;

Humblet, Yves ;

Bodoky, Gyorgy ;

Cunningham, David ;

Jassem, Jacek ;

Rivera, Fernando ;

Kocakova, Ilona ;

Ruff, Paul ;

Blasinska-Morawiec, Maria ;

Smakal, Martin ;

Canon, Jean Luc ;

Rother, Mark ;

Williams, Richard ;

Rong, Alan ;

Wiezorek, Jeffrey ;

Sidhu, Roger ;

Patterson, Scott D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (11) :1023-1034

← 1 2 3 4 5 6 →